US 11,964,953 B2
Substituted aminothiazoles as DGKzeta inhibitors for immune activation
Norbert Schmees, Berlin (DE); Ulrike Roehn, Berlin (DE); Dennis Kirchhoff, Berlin (DE); Kirstin Petersen, Berlin (DE); Mareike Grees, Berlin (DE); Nicolas Werbeck, Freiburg (DE); Benjamin Bader, Berlin (DE); Rienk Offringa, Heidelberg (DE); and Corinna Link, Heidelberg (DE)
Assigned to Bayer Aktiengesellschaft, Leverkusen (DE); and Deutsches Krebsforschungszentrum, Heidelberg (DE)
Filed by Bayer Aktiengesellschaft, Leverkusen (DE); and Deutsches Krebsforschungszentrum, Heidelberg (DE)
Filed on Sep. 14, 2022, as Appl. No. 17/944,922.
Application 17/944,922 is a continuation of application No. PCT/EP2021/060167, filed on Apr. 20, 2021.
Claims priority of application No. 20171280 (EP), filed on Apr. 24, 2020.
Prior Publication US 2023/0139936 A1, May 4, 2023
Int. Cl. C07D 277/42 (2006.01); A61P 35/00 (2006.01); C07D 277/46 (2006.01); C07D 417/06 (2006.01); C07D 417/10 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); C07D 471/08 (2006.01); C07D 487/04 (2006.01); C07K 16/28 (2006.01)
CPC C07D 277/42 (2013.01) [A61P 35/00 (2018.01); C07D 277/46 (2013.01); C07D 417/06 (2013.01); C07D 417/10 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 471/08 (2013.01); C07D 487/04 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07B 2200/07 (2013.01)] 26 Claims
 
1. A compound having the structure:

OG Complex Work Unit Chemistry
or a tautomer, hydrate, or solvate thereof, or a pharmaceutically acceptable salt of any of the foregoing.